Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02653976 is registered in ClinicalTrials.gov with Solasia Pharma K.K. as lead sponsor.

NCT NCT02653976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02653976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Lead sponsor
Solasia Pharma K.K.
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2016
Completion date
June 17, 2021
Enrollment
67 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma